Photo of Rajeev Rohatgi

Rajeev Rohatgi

  • ASSOCIATE PROFESSOR Medicine, Nephrology
Print ProfilePrint Profile



  • Nephrology

  • American Board of Internal Medicine


  • MD, New York University

  • Residency, Internal Medicine
    Mount Sinai Hospital

  • Fellowship, Renal Medicine
    Mount Sinai Hospital



Sodium transport in Autosomal Recessive PKD epithelia

Polycystic kidney disease (PKD) is a common genetic disease that is associated with a high morbidity and mortality. Autosomal dominant PKD (ADPKD) affects ~1:1,000 while autosomal recessive PKD (ARPKD) affects ~1:20,000 live births. Approximately 50 percent of patients with ADPKD develop end-stage renal disease (ESRD) by the sixth decade of life while most infants with ARPKD that survive beyond the perinatal period develop chronic renal failure by early adolescence. In PKD, cyst growth and expansion destroys normal renal parenchyma and leads to renal failure. ADPKD cysts arise from any tubular segment, "bud" off from the nephron, and no longer communicate with the tubule from which they originate. Cysts in ARPKD, however, are actually ectatic dilated collecting ducts which remain contiguous with the filtering nephron, allowing for urine to continue to flow through the dilated collecting system.

Evidence from experimental ADPKD models and human disease suggests that cyst formation and expansion arise, at least in part, from transepithelial solute and fluid secretion. In contrast to the latter observation, we have recently reported that ARPKD cystic collecting ducts, at least early in disease, reabsorb Na. Patch clamp analysis showed that apical Na channel activity in ARPKD cells is ~2 fold greater than that detected in age-matched human fetal collecting tubule (HFCT) cells. The additional observation that steady state expression levels of the and subunits of the apical epithelial Na channel (ENaC), the rate limiting step in Na absorption in the collecting duct, are higher in ARPKD than HFCT cells leads us to hypothesize that ARPKD is associated with upregulated Na absorption, presumably mediated by ENaC. We speculate that dysregulated Na transport contributes to the early onset of hypertension characteristic of this disease. Using assorted molecular (RT-PCR, Northern Blot, Western Blot) and physiologic (patch clamp, Ussing chamber) techniques on a human cell culture model, we plan to elucidate the mechanisms of Na transport in ARPKD renal cystic epithelia.


Woda CB, Leite Jr M, Rohatgi R, Satlin LM. Effects of luminal flow and nucleotides on [Ca(2+)](i) in rabbit cortical collecting duct. Am J Physiol Renal Physiol 2002 Sep; 283(3): F437-F446.

Rohatgi R, Gharvi A, Satlin LM. There's Gold in Them Ducts. J Pediatr Gastroenterol Nutr 2003 January; 36(1): 154-156.

(Review of Ward et al paper entitled The Gene Mutated in Autosomal Recessive Polycystic Kidney Disease Encodes a Large Receptor-Like Protein.)

Delgado MM, Rohatgi R, Khan S, Holzman IR, Satlin LM. Sodium and Potassium Clearances by the maturing kidney: clinical-molecular correlates. Pediatr Nephrol 2003 Aug; 18(8): 759-767.

Rohatgi R, Greenberg C, Burrow C, Wilson P, Satlin LM. Na Transport in Autosomal Recessive Polycystic Kidney Disease (ARPKD) Cyst-lining epithelial cells. J Am Soc Nephrol 2003 April; 14(4): 827-836.

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Dr. Rohatgi did not report having any of the following types of financial relationships with industry during 2014 and/or 2015: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.

Insurance Information

Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).

Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.

Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.

Edit profile in Sinai Central

Department of Nephrology

5 East 98th Street, 11th Floor
New York, NY 10029

Tel: 212-241-4060
Get Directions

Office Hours:
  • Monday 9:00am - 5:00pm
  • Tuesday 9:00am - 5:00pm
  • Wednesday 9:00am - 5:00pm
  • Thursday 9:00am - 5:00pm
  • Friday 9:00am - 5:00pm